ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...
Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a ...
Getting your Trinity Audio player ready... A Colorado board voted unanimously Friday to consider setting a maximum price for a drug to treat autoimmune diseases, launching the state into uncharted ...
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...
Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...
A Colorado board voted to move forward with setting a price ceiling on the arthritis drug Enbrel on Friday, a first-in-the-nation step that raises questions about whether a single state can reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback